Smith & Nephew PLC (SN) Cash Flow Statement
A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally.
Total Cash From Operating Activities Chart for Smith & Nephew PLC
Smith & Nephew PLC (SN) operating cash flow for FY2025 was GBP 1.3B, a 32.9% change from FY2024. Smith & Nephew PLC's operating cash flow grew from GBP 106.5M in 1991 to GBP 1.3B in 2025 (1132.2% over 34 years). Operating cash flow compound annual growth rate: 5-year CAGR of 7.0%, 10-year CAGR of 2.4%, 20-year CAGR of 8.4%.
Total Cash From Operating Activities (British Pounds)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- £8.92B
- Implied Share Price
- £10.66
- Enterprise Value
- £11.16B
- Revenue (TTM)
- £6.30B
- EBITDA
- £1.38B
- Profit Margin
- 10.08%
- Trailing P/E
- 19.73
- Forward P/E
- 13.09
- Price/Book (MRQ)
- 2.35
- Price/Sales (TTM)
- 1.42
- EV/EBITDA
- 9.68
- EV/Revenue
- 2.42
- Dividend Yield
- 3.71%
- Book Value
- £4.50
- Free Cash Flow (FY2025)
- £869.88M
- Free Cash Flow Yield
- 9.75%
Snapshot as of 27th August 2026 — not point-in-time controlled, may lag the live market by a few days.